Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
RMD · NYSE · United States · Surgical & Medical Instruments & Apparatus
In shortRESMED INC is profitable, generates cash and holds more cash than debt, with revenue growing (+9.9% last year).
Financial health
Strong
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 33.4% | 100/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 26.9% | 100/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 24.3% | 100/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 20.7% | 100/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 3.10× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.10× | 100/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | – | n/a |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 9.10 | 100/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 29.2% | 100/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 1.08× | 98/100 |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 5 of 5 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 5 | 100/100 |
| Revenue growth volatility | 3.4% | 98/100 |
| Operating margin volatility | 3.0% | 82/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 10.2% | 73/100 |
|---|---|---|
| EPS growth, 3-year average | 19.6% | 100/100 |
Weight in the score: 10%
Fiscal year 2026 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 3,578 | 4,223 | 4,685 | 5,146 | 5,653 |
| Cost of revenue | 1,554 | 1,867 | 2,030 | 2,091 | 2,202 |
| Gross profit | 2,024 | 2,356 | 2,655 | 3,055 | 3,452 |
| Research & development | 254 | 288 | 308 | 331 | 378 |
| Selling, general & admin | 738 | 874 | 917 | 993 | 1,120 |
| Operating income | 1,000 | 1,132 | 1,320 | 1,685 | 1,887 |
| Pre-tax income | 960 | 1,102 | 1,265 | 1,678 | 1,919 |
| Income tax | 181 | 204 | 244 | 277 | 396 |
| Net income | 779 | 898 | 1,021 | 1,401 | 1,523 |
| Diluted EPS | $5.30 | $6.09 | $6.92 | $9.51 | $10.43 |
| Diluted shares (millions) | 147 | 147 | 148 | 147 | 146 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
9.10 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
7/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 13, 2026